PDL1 expression is associated with longer postoperative, survival in adrenocortical carcinoma.

摘要: Adrenocortical carcinomas (ACCs) are heterogeneous cancers associated with a very poor prognosis. The improvement of prognostic tools and systemic therapy urgently needed. Targeting the immune system using checkpoint inhibitors such as PD1/PDL1 is an attractive novel therapeutic strategy for poor-prognosis tumors. Multiple clinical trials ongoing, including in advanced ACC. However, PDL1 expression has been studied ACC only one series 28 samples. Here, we have retrospectively analyzed mRNA 146 samples searched correlations between biological clinicopathological data, post-operative disease-free survival (DFS). was across "PDL1-high" tumors were not classical variables but longer DFS both uni- multivariate analyses. High signs cytotoxic local response. Supervised analysis "PDL1-low" identified robust 370-gene signature whose ontology suggested existence T-cell response, however, some degree exhaustion. In conclusion, refines prognostication high DFS. Clinical validation at protein level functional required to fully understand role Reactivation dormant tumor-infiltrating lymphocytes by PDL1-inhibitors could represent promising ACCs, supporting ongoing trials.